The Next Wave of
Neurological Medicines is Here.

We are committed to transforming the lives of patients with neurological and rare diseases.

We’re Changing the Game.

We are developing a pipeline of potentially best-in-class neurological assets discovered and optimized by a world-class G protein-coupled receptors (GPCRs) research team at Arena Pharmaceuticals. Many important categories of drugs target GPCRs, which are proteins that regulate numerous aspects of human physiology. Longboard is leveraging 20 years of research to develop the next generation of GPCR-targeted medicines.

Recent Press Releasess

10.04.2024

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Read More »

09.26.2024

Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome

Read More »

09.19.2024

Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome

Read More »

09.08.2024

Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Read More »

Live the
Longboard Life.

We are committed to improving the quality of life for individuals with devastating neurological conditions and strive to be the best possible teammates and colleagues. Learn more about our culture, benefits and open positions.

We show up
for patients.

The people living with, supporting and treating those with neurological conditions are at the center of what we do. Learn more about our commitment.